ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pyrazine-2-carboxylic acid. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

17 träffar

Bibliografisk träff 2017-02-06

Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells.

Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY, Meehan BS, Pediongco T, Birkinshaw RW, Chen Z, Wang H, D'Souza C, Kjer-Nielsen L, Gherardin NA, Godfrey DI, Kostenko L, Corbett AJ, Purcell AW, Fairlie DP, McCluskey J, Rossjohn J.

Nat Immunol · research support, non-u.s. gov't; journal article · DOI 10.1038/ni.3679

Bibliografisk träff 2012-06-29

pncA Mutations in the Specimens from Extrapulmonary Tuberculosis.

Lee J, Yun YJ, Kqueen CY, Lee JH, Kim HY, Kim YR, Kook YH, Lee KH.

Tuberc Respir Dis (Seoul) · research-article; journal article · DOI 10.4046/trd.2012.72.6.475

Bibliografisk träff 2012-06-01

The chemotherapy of tuberculosis: past, present and future.

Mitchison D, Davies G.

Int J Tuberc Lung Dis · historical article; research-article; review; journal article · DOI 10.5588/ijtld.12.0083

Bibliografisk träff 2012-02-28

A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.

Zimic M, Loli S, Gilman RH, Gutierrez A, Fuentes P, Cotrina M, Kirwan D, Sheen P.

Microb Drug Resist · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1089/mdr.2011.0207

Bibliografisk träff 2012-01-01

Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.

Kim HJ, Kwak HK, Lee J, Yun YJ, Lee JS, Lee MS, Min SY, Park SK, Kang HS, Maeng YH, Kim SY, Kim SY, Kook YH, Kim YR, Lee KH.

Int J Tuberc Lung Dis · research support, n.i.h., intramural; research support, non-u.s. gov't; journal article · DOI 10.5588/ijtld.10.0739

Bibliografisk träff 2011-10-17

Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Zimic M, Fuentes P, Gilman RH, Gutiérrez AH, Kirwan D, Sheen P.

Tuberculosis (Edinb) · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.tube.2011.09.002

Bibliografisk träff 2011-08-29

Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Lu P, Haagsma AC, Pham H, Maaskant JJ, Mol S, Lill H, Bald D.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00507-11

Bibliografisk träff 2011-08-11

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y.

Science · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1126/science.1208813

Bibliografisk träff 2011-06-29

Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.

Sayahi H, Zimhony O, Jacobs WR, Shekhtman A, Welch JT.

Bioorg Med Chem Lett · research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.bmcl.2011.06.055

Bibliografisk träff 2011-01-24

Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide.

Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0015785

Bibliografisk träff 2011-01-01

Antimycobacterial evaluation of pyrazinoic acid reversible derivatives.

Dolezal M, Dolezal M, Kesetovic D, Zitko J.

Curr Pharm Des · research support, non-u.s. gov't; review; journal article · DOI 10.2174/138161211798194477

Bibliografisk träff 2010-11-01

Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.

Seiner DR, Hegde SS, Blanchard JS.

Biochemistry · research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/bi1011157

Bibliografisk träff 2010-07-01

Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells.

Tostmann A, Aarnoutse RE, Peters WH, Richard PN, Boeree MJ.

Drug Chem Toxicol · research support, non-u.s. gov't; journal article · DOI 10.3109/01480540903449715

Bibliografisk träff 2010-04-09

The near future: improving the activity of rifamycins and pyrazinamide.

Mitchison DA, Fourie PB.

Tuberculosis (Edinb) · review; journal article · DOI 10.1016/j.tube.2010.03.005

Bibliografisk träff 2010-02-01

QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.

Fernandes JP, Pasqualoto KF, Felli VM, Ferreira EI, Brandt CA.

Arch Pharm (Weinheim) · validation study; journal article · DOI 10.1002/ardp.200900216

Bibliografisk träff 2009-12-04

Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Zimic M, Sheen P, Quiliano M, Gutierrez A, Gilman RH.

Infect Genet Evol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.meegid.2009.11.016

Bibliografisk träff 2009-04-01

Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats.

Akashi I, Kagami K, Hirano T, Oka K.

J Pharm Pharmacol · journal article · DOI 10.1211/jpp/61.04.0009